Repaglinide Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IA/0016 
A.7 - Administrative change - Deletion of 
21/01/2022 
Annex II and 
manufacturing sites 
PL 
IB/0015 
B.II.b.3.z - Change in the manufacturing process of 
15/03/2021 
n/a 
the finished or intermediate product - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IAIN/0014/G 
This was an application for a group of variations. 
21/08/2020 
01/09/2021 
Annex II and 
PL 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0013 
B.II.b.3.a - Change in the manufacturing process of 
11/05/2020 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
II/0009/G 
This was an application for a group of variations. 
12/12/2019 
n/a 
B.II.a.3.b.1 - Changes in the composition 
(excipients) of the finished product - Other excipients 
- Any minor adjustment of the quantitative 
composition of the finished product with respect to 
excipients 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.1.g - Change in the specification parameters 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
IAIN/0012/G 
This was an application for a group of variations. 
03/12/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
Page 3/6 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
IA/0011 
B.III.1.a.2 - Submission of a new/updated or 
11/07/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0010 
B.II.b.2.a - Change to importer, batch release 
05/03/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
T/0008 
Transfer of Marketing Authorisation 
01/02/2019 
25/02/2019 
SmPC, 
Labelling and 
PL 
IAIN/0007/G 
This was an application for a group of variations. 
04/10/2018 
25/02/2019 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not including batch control/testing 
IA/0006 
B.III.1.a.2 - Submission of a new/updated or 
16/12/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
R/0005 
Renewal of the marketing authorisation. 
21/07/2016 
19/09/2016 
SmPC, Annex 
II, Labelling 
and PL 
IAIN/0004/G 
This was an application for a group of variations. 
15/09/2015 
19/09/2016 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IAIN/0003 
C.I.8.a - Introduction of or changes to a summary of 
30/08/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0002 
Update section 4.5 of SmPC in order to include a new 
26/07/2012 
19/09/2016 
SmPC, Annex 
II, Labelling 
and PL 
drug-drug interaction with deferasirox after CHMP 
adoption of safety variation on 15 March 2012 to the 
Marketing Authorisations of Novonorm and Prandin 
(EMEA/H/C/XXXX/WS/223). Section 2 of the Package 
leaflet is updated in accordance. 
PI was also updated according to the latest QRD 
template. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Page 6/6 
 
 
 
 
 
 
 
 
 
